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Prosaposin activates the androgen receptor
and potentiates resistance to endocrine
treatment in breast cancer
Azlena Ali1,2†, Laura Creevey1†, Yuan Hao3, Damian McCartan1, Peadar O’Gaora3, Arnold Hill1,2, Leonie Young1
and Marie McIlroy1*
Abstract
Introduction: HOX genes play vital roles in growth and development, however, atypical redeployment of these
genes is often associated with steroidal adaptability in endocrine cancers. We previously identified HOXC11 to be
an indicator of poor response to hormonal therapy in breast cancer. In this study we aimed to elucidate genes
regulated by HOXC11 in the endocrine resistant setting.
Methods: RNA-sequencing paired with transcription factor motif-mapping was utilised to identify putative HOXC11
target genes in endocrine resistant breast cancer. Validation and functional evaluation of the target gene, prosaposin
(PSAP), was performed in a panel of endocrine sensitive and resistant breast cancer cell lines. The clinical significance of
this finding was explored in clinical cohorts at both mRNA and protein level.
Results: PSAP was shown to be regulated by HOXC11 in both tamoxifen and aromatase inhibitor (AI) resistant cell lines.
Transcript levels of HOXC11 and PSAP correlated strongly in samples of primary breast tumours (r = 0.7692, n = 51).
PSAP has previously been reported to activate androgen receptor (AR) in prostate cancer cells. In a panel of breast
cancer cell lines it was shown that endocrine resistant cells exhibit innately elevated levels of AR compared to their
endocrine sensitive counterparts. Here, we demonstrate that stimulation with PSAP can drive AR recruitment to a
hormone response element (HRE) in AI resistant breast cancer cells. Functionally, PSAP promotes cell migration
and invasion only in AI resistant cells and not in their endocrine sensitive counterparts. In a cohort of breast cancer
patients (n = 34), elevated serum levels of PSAP were found to associate significantly with poor response to endocrine
treatment (p = 0.04). Meta-analysis of combined PSAP and AR mRNA are indicative of poor disease-free survival in
endocrine treated breast cancer patients (hazard ratio (HR): 2.2, P = 0.0003, n = 661).
Conclusion: The HOXC11 target gene, PSAP, is an AR activator which facilitates adaptation to a more invasive phenotype
in vitro. These findings have particular relevance to the development of resistance to AI therapy which is an emerging
clinical issue. PSAP is a secreted biomarker which has potential in identifying patients failing to exhibit sustained response
to hormonal treatment.
Introduction
Breast cancer has the highest incidence and second high-
est mortality rate among cancers in women worldwide [1].
The median age of diagnosis for breast cancer is 61 years
and the majority of patients are postmenopausal at time
of diagnosis. Endocrine therapy has been the mainstay for
patients with hormone receptor-positive breast cancer
(approximately 75 %) since the inception of the steroid
receptor modulator, tamoxifen, in the latter part of the
20th century. One of the major advances in breast can-
cer therapy in the past decade has been the widespread
endorsement of aromatase inhibitors (AIs) as first-line
therapy for postmenopausal patients with hormone
receptor-positive breast cancer. AIs work by abrogating
the activity of the enzyme aromatase (Cyp 19), which
converts circulating androgens into estrogen within dif-
ferent body compartments including mammary adipose
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tissue [2–4]. Clinical trials into the efficacy and side-
effects of these drugs in comparison to tamoxifen have
heralded them as the main choice of adjuvant endocrine
therapy for postmenopausal breast cancer [5]. Despite the
huge advances in the treatment and management of breast
cancer the development of drug resistance remains an un-
resolved problem. For hormone receptor-positive breast
cancer, drug resistance occurs in approximately 25 % of
cases, which accounts for approximately 50,000 breast
cancer recurrences/annum in the US alone [6]. In some
studies the development of resistance to endocrine ther-
apy is estimated to be as high as 30−60 % [7]. This may be
due in part to adaptive hypersensitivity of the intact estro-
gen receptor (ER) [5], selective co-activator enhancement
[8], or a shift to growth-factor pathway-dependent cell
growth which is well-known to contribute to endocrine
treatment failure [9, 10]. Approximately 75 % of breast
cancers also express androgen receptor, which includes a
proportion of triple-negative tumours [11, 12]. With
regards to the role of androgen signalling and breast
cancer survival there is conflicting evidence. In ER-positive
tumours it is reported that androgen receptor (AR) expres-
sion is beneficial and it is suggested that it may compete
for ER binding sites on the DNA, thereby blocking
estrogen-stimulated transcription of pro-proliferative
genes [13]. Other reports however claim that high cir-
culating levels of androgens are associated with in-
creased breast cancer risk in both the premenopausal
and postmenopausal setting [14] and that elevated levels
of AR are pro-metastatic [15]. More recent studies have
highlighted the tumour promotional effects of the AR par-
ticularly in the event of estrogen disruption [16–20].
Previous work from this laboratory investigating endo-
crine resistance in breast cancer has shown the develop-
mental transcription factor HOXC11 to be a strong
predictor of metastasis and poor disease-free survival
(DFS), independent of receptor status, tumour size,
nodal status and grade [21]. Homeobox genes encode a
family of 39 proteins of which HOXC11 is a member.
These proteins act as developmental transcription fac-
tors involved in growth and differentiation [22, 23]. They
play essential roles in body patterning and spatial iden-
tity, hence they are akin to a form of cellular global
positioning system [24]. Maintenance of HOX gene ex-
pression patterns are under complex epigenetic regula-
tion. The homeobox transcription factors are known to
be regulated by steroids during embryogenesis; however,
there is a growing body of evidence to suggest that these
genes are also architects of steroidal regulation in endo-
crine tumours [21, 25–27]. Studies by Norris et al. [28]
demonstrate that HOXB13 can interact with the AR to
alternately suppress or activate AR-responsive genes in a
promoter-dependent manner. Moreover, recent studies
into the upregulation of the HOXC locus in prostate
cancer have demonstrated that its ability to modulate an-
drogen signalling is due to the abrogation of coactivator re-
cruitment to direct androgen target genes [25]. Thus, there
is rapidly accumulating evidence to suggest that HOX genes
and in particular HOXC genes are key players in modu-
lating steroid signalling in endocrine tumours.
To further our understanding of HOXC11 and the role
it plays in the development of endocrine resistance and
steroidal adaptability we undertook an RNA-seq experi-
ment to identify HOXC11 target genes in resistant breast
cancer. We identified 1,919 genes, and conducted motif
mapping to identify potential direct target genes of the
transcription factor HOXC11. Analysis of the target genes
identified a common novel motif with significant similarity
to an AR response element. From these studies we identi-
fied prosaposin (PSAP) as a HOXC11 regulated gene.
PSAP is a purported AR activator associated with meta-
static potential in a number of neoplasms [29–31]. This
study supports the hypothesis that expression of HOXC11
and the subsequent secretion of PSAP can expedite endo-
crine resistance to aromatase inhibitor therapy via tumour
promotional activation of the AR.
Methods
Cell culture
Endocrine-sensitive MCF-7 (American Type Culture Col-
lection (ATCC) Virginia, USA ) and tamoxifen-resistant
LY2 cells (kind gift from R. Clarke, Georgetown, DC,
USA) were grown as previously described [21]. MCF7-
derived AI-sensitive cells (Aro) were developed in house.
MCF7 Aro-derived letrozole-resistant cells (LetR) and
anastrozole-resistant cells (AnaR) were created by long-
term treatment of Aro with letrozole (Novartis, Basel,
Switzerland) or anastrozole (AstraZeneca, Macclesfield,
UK) [21]. LY2, LetR and AnaR cells were utilised to model
endocrine resistance developed through long-term adapta-
tion to hormonal therapy. MDA-MB-453, SKBR3 and
LNCaP cells were acquired from ATCC and maintained as
recommended. Cells were maintained in steroid-depleted
medium for 72 hours before treatment with hormones.
All cells were incubated at 37 °C under 5 % CO2 in a hu-
midified incubator. All in-house cells were authenticated
and are routinely verified as endocrine resistant.
siRNA transfection
HOXC11 was silenced by transient transfection using an
experimentally verified pool of siRNA (Flexitube, Qiagen,
Manchester, UK) as previously described [21]. All transfec-
tions were carried out using Lipofectamine 2000 transfec-
tion reagent according to manufacturer’s instructions
(Invitrogen, Thermo Fisher, Warrington, UK) and a non-
targeting siRNA negative control (Ambion, Thermo Fisher,
Warrington, UK) was used as a control for all siRNA
experiments.
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RNA extraction, library preparation and RNA sequencing
(RNA-seq)
To assess the global effects of HOXC11 in endocrine-
resistant breast cancer cells we performed RNA-seq on
LY2 cells, which were transfected with either siRNA target-
ing HOXC11 (siRNA-HOXC11) or a scrambled negative
control siRNA (scrambled) in the presence of tamoxifen
(10−8 M). Knockdown was verified by Taq-man quantitative
reverse transcription PCR (qRT-PCR) prior to library prep-
aration. RNA (10 μg) was extracted using an Oligotex
mRNA kit (Qiagen) as per manufacturer’s instructions
(n = 4). RNA was reverse transcribed followed by
mRNA library preparation and sequencing based on a
protocol outlined by Wilhelm et al. [32]. Sequencing
was performed on an Illumina Genome Analyzer II (GAII)
(54 million reads per sample on average). Four independ-
ent biological libraries were prepared for each sample to
facilitate the detection of expression and estimation of
variance. Multiplexing was achieved using barcoding
adapters designed in house. After quality checks two of
the replicates per sample group were then subjected to
further downstream analysis.
Short reads of 36 bp in length were aligned to human ref-
erence genome (UCSC hg19, Ensembl GRCh37 release 64)
using the splice-aware aligner Tophat [33] allowing up
to 50 multiple mapping locations and no more than 2
mismatches across each read. Differential expression genes
(DEGs) were detected by using the Cufflinks/Cuffdiff pro-
gram (v v1.0.2) [34].
Estrogen response element (ERE) and androgen response
element (ARE) motif analysis
The AR and ER position frequency matrices (PFM) were
downloaded from the JASPAR database [35]. The PFM
was then converted to positive weight matrices (PWM)
using the MEME suite programme [36]. A 400-bp-sized
window surrounding starting sites of HOXC11 target genes
was selected for motif searching. FIMO [37], a MEME suite
programme, was used to identify the AR/ER motifs near
the HOXC11 target gene start site with a p value sig-
nificance cutoff set at 0.001. Genes having at least one
significant hit were kept, and for genes with multiple sig-
nificant hits, only the best one is reported.
HOXC11 motif analysis
The global mapping of the HOXC11 motif was per-
formed using the TFfind programme [38]. The HOXC11
motif frequency matrix (PFM) and representing logo were
identified from the UniPROBE database [39]. The first bp
and the last 3 bp of this motif were deemed to have low
information content and removed from further consider-
ation, resulting in a full motif of 12 bp (consensus se-
quence: AANGTCGTAAAA) being employed for binding
site discovery. Mapping was carried out in the promoter
region (5000 bp upstream of TSSs) of all annotated hu-
man genes (UCSC hg19, Ensembl GRCh37 release 64).
Resultant hits that met the predefined cutoff (≥0.9; 1 de-
notes a perfect match) were kept and associated with cor-
responding gene symbols based on the UCSC kgXref
table. Overlaps between the DEGs from the siRNA-
HOXC11 RNA-seq data and those containing HOXC11
motif in their promoters were reported.
Chromatin immunoprecipitation
LY2 cells were treated with tamoxifen (10−8 M), estrogen
(10−8 M) or vehicle. LetR cells were treated with andro-
stenedione (Andro, 10−7 M), estrogen (10−8 M) or vehicle.
Chromatin immunoprecipitation (ChIP) was performed as
previously described [21]. Mouse anti-HOXC11 (6 μg)
(Santa Cruz Biotechnology (SCBT), Texas, USA) was
added to the supernatant fraction and incubated overnight
at 4 °C with rotation. Proteins were un-crosslinked, and
primers were used to amplify the DNA −581 to −116 of
the PSAP proximal promoter that harbors a HOXC11
binding site and a hormone response element (HRE). PSAP
proximal promoter primers were forward: CCCGCTAC
TACAATGGGCTA, and reverse: GGGGAGGAGTGAG
GAAGAAC. Distal non-promoter control primers were
forward: TGGTGAGGTTGTATCCACGA, and reverse:
CCACTCATGCAATGACCGTA.
PSAP ELISA
A commercially available PSAP ELISA (Cusabio, Stratech,
Suffolk, UK) was used to assess serum levels of secreted
PSAP in conditioned medium from breast cancer cell lines
in vitro and also in blood serum from consenting patients
with breast cancer (n = 34) (see “Clinical Samples” for
more detail).
Western blotting
Protein from breast cancer cell lines were lysed, electro-
phoresed, and immunoblotted with a rabbit anti-human
AR (1:1000 dilution) (sc-816, SCBT), β-actin loading
control (Sigma Aldrich, UK) and a corresponding horse-
radish peroxidase-conjugated secondary antibody (Dako,
Den).
HOXC11 transfection
A vector construct pCMV.SPORT-HOXC11 (Life technolo-
gies, Thermo Fisher, UK) was used to transiently overex-
press HOXC11 in MCF7 cells. MCF7 were seeded at 2.5
× 105 cells in a 6-well plate and incubated overnight.
Lipofectamine 2000 (Life Technologies) was used to
transfect the cells with pCMV.SPORT-HOXC11 versus
empty vector (2 μg) according to the manufacturer’s
instructions.
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TransAM AR assay
The TransAM assay (Active Motif, California, USA) was
modified for use with an AR rabbit anti-human antibody
(sc-816, SCBT). Optimal nuclear lysate and antibody con-
centrations were determined using steroid-dependent
LNCaP prostate cancer cell nuclear lysate as a positive
control (Additional file 1: Figures S1A and B). LetR breast
cancer cells were cultured in the presence of metribolone,
a synthetic androgen (R1881, Sigma Aldrich) (10 nmol/L)
or recombinant human PSAP (rhPSAP) (10 ng/ml) for 1
hour. Cells were pelleted and nuclear protein isolated
using a NE-PER kit (Pierce, Thermo Fisher). The assay
was then performed according to manufacturer’s instruc-
tions using LetR nuclear cell lysate (20 μl) and AR anti-
body at a 1:250 dilution (Additional file 1: Figure S1B). On
completion of the assay the plate was read at an ab-
sorbance of 450 nm (0.1sec) using a Victor2 plate reader
(Perkin Elmer, Dublin, Ire).
Treatment of cells in vitro with rhPSAP
Lyophilized rhPSAP protein (Abnova, Taiwan) was recon-
stituted in storage buffer (50 mM Tris-HCI, 10 mM
reduced Glutathione, pH = 8.0). LetR cells were steroid-
depleted for 72 hours prior to the addition of recombinant
PSAP protein (10 ng/ml). Cells were cultured for a fur-
ther hour (TransAM) or for 24 hours (protein analysis)
under standard conditions, before the cell monolayer was
washed with PBS, trypsinised and the cells pelleted for fur-
ther analysis.
Nuclear translocation assay
Uncoated glass microscope slides (BDH Laboratory sup-
plies, UK) were cleaned with 100 % ethanol, air-dried
and placed in sterile 6-well tissue culture dishes. MCF7
and LetR cells were seeded at 6 × 102 onto a coverslip in
steroid-depleted media for 72 hours prior to treatment.
For individual treatments, rhPSAP (10 ng/ml) and enzaluta-
mide (Enza, 10 μM, Selleckchem, Stratatech) were added to
the cells for 3 hours. For dual rhPSAP and Enza treatment,
cells were pretreated with Enza (10 μM) for 2 hours and
then co-treated with rhPSAP (10 ng/ml) in the presence of
Enza for a further hour (3 hours total treatment time). Cells
were washed in PBS and fixed in methanol for 10 minutes
and permeabilised with 0.1 % triton X-100. Samples were
then blocked with 10 % goat serum for 1 hour at room
temperature (RT) and incubated with an antibody against
AR (N20, sc-815 1:50; SCBT) in 10 % human serum for 90
minutes at RT. Samples were incubated with secondary
antibody anti-rabbit Alexa Fluor 488 (1:200) (Thermo
Fisher) in 10 % human serum for 1 hour at RT. The nu-
clei were stained with 4′,6-diamidino-2-phenylindole
(1 μg/ml) for 1 minute. Samples washed with dH2O and
coverslips containing treated samples were mounted onto
slides using fluorescent mounting media (Dako). Cells
were visualised by fluorescent microscopy using the Cell-
Sens Olympus software. The nuclear translocation of AR
(the intensity of AR signal within the nucleus) was quan-
tified in a minimum of 50 cells using ImageJ software.
In vitro cell migration assay
Uncoated glass microscope slides were cleaned with 100 %
ethanol, air-dried and placed in sterile 6-well tissue culture
dishes. Cells were plated (LetR 3 × 105 cells/2ml growth
medium per well, MCF7 2.5 × 105 cells/2ml growth
medium per well) and allowed to adhere for 24 hours
at 37 °C under standard conditions. Cell monolayers were
wounded using the pointed edge of a 20−200-μl yellow pip-
ette tip to score laterally and through the longest length of
the cell monolayer. All slides were wounded aseptically at
the same time. Cells were treated with 0.1, 1.0, and 10.0 ng/
ml rhPSAP and vehicle (Tris–HCl 5 nM). Five images were
captured along the length of the scratch at 0, 6 and 24
hours. Five measurements were made within each image
using CellSens Entry 1.8 software. Each treatment group
consisted of three slides and the entire experiment was re-
peated in triplicate.
Transwell invasion assay
Twenty-four-well Biocoat matrigel invasion chambers
(Corning, USA) were prepared as per manufacturer’s
instructions: 5 × 104 cells/500 μl (either MCF7 or LetR)
were seeded in serum-free medium into the upper cham-
ber of the insert, and 10 % serum medium was added to
the lower chamber to act as a chemoattractant. rhPSAP
(10 ng/ml) was added to the upper chambers versus Tris–
HCl (5 nM) control. Transwell plates were incubated for
48 hours under normal conditions, 37 °C, 5 % CO2. If cells
had been transfected with siRNA the experiment was ex-
tended to 60 hours. Inserts were then washed with PBS
(×2) and cells in the upper chamber removed using a cot-
ton tip (Johnston & Johnston, Ire); cells remaining in the
underside of the insert were then fixed in methanol
(10 minutes), and 0.5 % crystal violet (Cruinn, Ire) was
added to the lower chamber to visualize cells that had
invaded across the membrane. Inserts were washed in
dH2O (×2). Representative images (×4 magnification)
(CellSens Olympus software) were then evaluated using
Image J software to quantify the results. A minimum of
five fields of view were evaluated per well.
MTS assay
LetR cells were steroid-depleted for 72 hours and then
seeded into a 24-well plate prior to the addition of
bicalutamide (Bica) (1 μM) (Sigma Aldrich) or vehicle
(dimethyl sulfoxide DMSO; 0.01 %) to regular growth
medium. MTS reagent (Sigma Aldrich) was added after
2, 3 and 4 days respectively and the resultant
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colorimetric outputs analyzed by measuring the absorb-
ance at 490nm using a spectrophotometer (Perkin Elmer).
Colony forming assay
LetR cells were steroid depleted for 72 hours prior to be-
ing seeded into 6-well plates at a density of 5 × 102 cells
per well. The cells were treated with vehicle (DMSO;
0.01 %) or Bica (1 μM) and androstenedione (100 nmol/
L), and each plate was incubated over 4, 8, or 12 days.
Media containing treatments were changed every 48 hours
up until the end of each time point. After each time point
was reached, cells were washed with PBS, fixed with
methanol-glacial acetic acid and stained with 0.5 %
crystal violet solution (Cruinn).
Clinical samples
Preoperative blood serum was collected from patients
undergoing surgery for the resection of a clinically di-
agnosed primary breast tumour: 7-ml blood samples
were taken in non-heparinised tubes, allowed to clot at
RT for approximately 30 minutes and separated in a
cooled (4 °C) centrifuge at 2,000 g for 10 minutes.
Serum was stored as 0.5-ml aliquots/cryovials and placed
in a freezer at −80 °C within 2 hours of being obtained. All
patients provided written consent and are currently en-
rolled on a clinical trial (ICORG – 09–07), ethical approval
was sought and granted by the appropriate Research
(Medical Ethics) Committees at Beaumont and Waterford
Regional Hospital (Ire). Clinical pathology data including
receptor status, tumour grade, nodal status, and endocrine
therapy have been collated. The median follow-up period
for the cohort was 35 months.
HOXC11 and PSAP mRNA correlation in clinical datasets
The Cancer Genome Atlas (TCGA) breast cancer RNA-seq
dataset was evaluated to determine correlation between
PSAP and HOXC11 mRNA in a supplementary clinical
cohort. The TCGA data were classified based on breast
cancer subtypes (luminal A, luminal B, human epidermal
growth factor receptor (Her)2 over-expressing and basal)
and each subtype was assessed for correlation (Spearman)
between PSAP and HOXC11. In addition, samples with
high AR expression (upper quartile) were also selected
and the Spearman’s correlation between HOXC11 and
PSAP calculated for this subgroup. A hazard ratio (HR)
curve was also generated for PSAP based on these data.
Meta-analysis of PSAP mRNA expression and breast cancer
patient survival
BreastMark [40] is an algorithm that enables the identifica-
tion of subsets of gene transcript/miRNAs that are associ-
ated with disease progression in breast cancer and its
subtypes. High levels of PSAP and/or AR mRNA were
evaluated in endocrine-treated datasets.
Statistical analysis
Graphpad Prism was used for the majority of statistical ana-
lysis. Univariate analysis was conducted using Fisher exact
test for categorical variables. A p value of less than 0.05 was
considered to be significant. Significance for quantitative
data was evaluated by repeated measures one-way analysis
of variance (ANOVA) for treatments over time and the
unpaired, two-tailed Student t test was used to compare
means. Spearman’s rank coefficient was used to deter-
mine correlation between variables.
Data accession code
RNA-seq data are available from the Gene Expression
Omnibus (GEO) database (GSE71139).
Results
Prosaposin (PSAP) was identified as a putative HOXC11
target gene from RNA-sequencing of endocrine-resistant
breast cancer cells in which HOXC11 was knocked down
Expression levels of 1,919 genes were shown to be signifi-
cantly altered after HOXC11 knockdown in endocrine-
resistant breast cancer cells in vitro (Fig. 1a (i)). The DEGs
included 977 downregulated genes (see Additional file 2)
(See figure on previous page.)
Fig. 1 Prosaposin (PSAP) was identified as a putative HOXC11 target gene from RNA-sequencing (RNA-seq) of endocrine-resistant breast cancer
cells in which HOXC11 was knocked down. a (i) RNA-seq was performed on mRNA from endocrine-resistant breast cancer cells (LY2) in which
HOXC11 had been silenced (n = 2): 1,919 hits (cutoff >= 0.95), corresponding to 1,243 Entrez gene IDs were identified. TFFind, a motif mapping
programme, was used to search for the HOXC11 motif (consensus sequence: GTCGTAAA) in all annotated human genes from UCSC (26,648
sequences). The analysis of these data resulted in the identification of 711 genes putatively regulated by HOXC11. (ii) Breakdown of RNA subtype
percentages identified in RNA-seq screening. b De novo motif identification was performed on sequences of HOXC11 targets that harbour
hormone response elements using the MEME program resulting in the identification of a novel motif (e-value: 1.3e-1337). The novel motif has
significant similarity to androgen receptor (AR) (p value: 2.26e-6) and NR3C1 (glucocorticoid receptor (GR)) (p value: 2.81e-4). c AR motif analysis
of total HOXC11 target genes shows that approximately 60 % contain an androgen response element (ARE) in the proximal promoter region.
d Merging RNA-sequencing and HOXC11 transcription factor motif-mapping datasets yielded a total of 29 genes, which were then ranked by
magnitude of fragments per Kilobase of transcript per million. e Validation of the putative HOXC11 target gene, PSAP, was confirmed by performing
chromatin immunoprecipitation to determine recruitment of HOXC11 to the PSAP promoter in LY2 (tamoxifen resistant) cells cultured in the
presence of tamoxifen versus vehicle. Results are representative of three separate experiments
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and 942 upregulated genes (see Additional file 3). The se-
quencing experiment was designed to focus on poly (A)
transcripts and as a result over 64 % (1,256) of these DEGs
were protein-coding (Fig. 1a (ii)). HOXC11 was verified to
be silenced from the RNA-seq data along with selected
target gene validation (Additional file 4: Figure S2a (i-ii)).
ARE and ERE motif analysis was performed on all tar-
get genes and 1,170 genes were found to harbour an AR
binding element (Additional file 5) and 1,558 genes con-
taining an ER binding site (Additional file 6). A total of
949 gene targets were identified that harbour both HREs
(Fig. 1b). In order to evaluate whether these HREs are pre-
dominately ARE or ERE, we evaluated the left half of both
motifs by selecting 10 bp from each of the matched-
sequences, which covers either position 2–11 of ER or
position 1–10 of AR. De novo motif identification was per-
formed on these sequences using the MEME programme.
This resulted in the identification of a novel motif (e-value:
1.3e-1337) (Fig. 1b) returned from MEME which was then
compared to all known motifs annotated in the JARSPAR
database (JARSPAR CORE 2014) using the TOMTOM
programme [35, 36]. The top matched motif was shown to
be AR (p value: 2.26e-6) (Additional file 4: Figure S2b) and
the second most similar motif is NR3C1 (glucocorticoid re-
ceptor (GR)) (p value: 2.81e-4). Further analysis of the AR
binding sites in HOXC11 target genes showed that approxi-
mately 60 % of the 1,919 genes are positive for a proximal
promoter ARE (Fig. 1c).
RNA-seq data was then merged with HOXC11 motif
mapping resulting in the identification of 29 putative
direct target genes (Fig. 1d). The list of genes was ranked
by magnitude of fragments per kilobase of transcript per
million (FPKM) mapped reads to ensure ample abundance
of transcript for validation purposes. This resulted in
PSAP being identified and validated as the top ranked
gene exhibiting differential expression when HOXC11
is knocked down. HOXC11 recruitment to the PSAP
promoter was verified by ChIP analysis performed on the
endocrine-resistant LY2 cells. It was noted that HOXC11
is recruited to the PSAP promoter (−581 to −116) under
basal conditions but that levels are enhanced when cells
are cultured in the presence of tamoxifen (Fig. 1e).
HOXC11 is recruited to the PSAP promoter in vitro when
estrogen signalling is disrupted
Evaluation of HOXC11 recruitment to the PSAP promoter in
LetR cells was evaluated by ChIP. HOXC11 was present on
the promoter when cells were treated with androstenedione
but its recruitment was markedly diminished when
cells were treated with estrogen, this loss of HOXC11 re-
cruitment was also observed in LY2 cells treated with estro-
gen (Fig. 2a). These data collectively led us to hypothesize
that HOXC11 recruitment to, and subsequent transcrip-
tion of, the PSAP gene occurs when normal estrogen sig-
nalling pathways have been disrupted by long-term
endocrine treatment (Fig. 2b). Evaluation of HOXC11
regulation of PSAP in tamoxifen and AI-resistant breast
cancer cell lines showed a concomitant decrease in PSAP
mRNA when HOXC11 was knocked down (Fig. 2c (i-ii)).
To determine if these genes are correlated in clinical
samples, HOXC11 and PSAP mRNA was assessed in a
cohort of primary breast tumours (n = 51). Transcript levels
of HOXC11 and PSAP mRNA were found to correlate
significantly in primary breast tumour tissue (rS = 0.7745,
p <0.0001) (Fig. 2d).
PSAP, a known AR activator, is readily detectable in breast
cancer cells that have high endogenous levels of HOXC11
and AR protein: over-expression of HOXC11 induces nuclear
translocation of AR in MCF7 cells
PSAP is a secreted protein that is detectable in conditioned
medium from breast cancer cell lines. A commercially
available ELISA was used to assess levels of secreted
PSAP in breast cancer cell-conditioned media. Higher
levels of PSAP protein were detectable in all endocrine-
resistant cell lines (LY2, LetR and AnaR) compared to their
endocrine-sensitive counterparts (MCF7 and Aro) (Fig. 3a).
PSAP has been previously reported to induce AR protein
in prostate cancer cells [30]. Western blot analysis of a
range of cell lines was performed to evaluate if there is
an association between elevated levels of PSAP and nuclear
AR protein in breast cancer cells. MDA-MB-453, an apo-
crine breast cancer cell line (ER−, PR−, HER2−, AR+) was
used as a positive control and SKBR3 (ER−, PR−, HER2+,
AR-low) as a negative control. Elevated levels of AR were
(See figure on previous page.)
Fig. 2 HOXC11 is recruited to the prosaposin (PSAP) promoter when estrogen signalling is disrupted. a HOXC11 is present on the PSAP promoter in
letrozole-resistant (LetR) cells cultured in androstenedione but not estrogen. HOXC11 is not present on the PSAP promoter in LY2 (tamoxifen (Tam) resistant)
cell cultures in estrogen. Cycle threshold (ct) values were not detected for distal-promoter control reactions for any sample. Error bars are representative of
mean ± standard error of the mean from three separate experiments (LetR) and two separate experiments (LY2). b In summary, HOXC11 is recruited to the
PSAP promoter in endocrine-resistant breast cancer cells in which estrogen signalling has been disrupted. c (i) Expression of PSAP mRNA is
significantly reduced in LY2 cells following silencing of HOXC11 by siRNA. (ii) Expression of PSAP mRNA is significantly reduced in LetR cells
following silencing of HOXC11 by siRNA. Results are representative of three separate experimental replicates. d HOXC11 and PSAP mRNA levels
were evaluated by qRT-PCR from RNA extracted from primary breast cancer specimens (n = 51). Spearman’s rank test was used to evaluate correlation
between PSAP and HOXC11 transcripts (r = 0.7745: p <0.0001). *p <0.05, **p <0.001, ***p <0.0001). Andro androstenedione, HRE hormone
response element
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detected in both tamoxifen (LY2)- and AI (LetR)-resistant
cell lines and were virtually undetectable in the parental
MCF7 cells (Fig. 3b (i-ii)). Transient overexpression of
HOXC11 in MCF7 cells resulted in a significant increase in
the level of nuclear AR compared to the levels observed in
an empty vector control (Fig. 3c (i-ii)). Consolidation of
these results with HOXC11 protein expression status [21]
shows that endocrine-resistant cells have elevated levels of
HOXC11, PSAP and AR protein when compared to
endocrine-sensitive MCF7 cells (illustrated in Fig. 3d).
AR is upregulated and transcriptionally activated in LetR
cells treated with recombinant PSAP; AR activation by PSAP
can be diminished by co-treatment with the anti-AR drug
enzalutamide
Treatment of LetR cells with rhPSAP (10 ng/ml) upregulates
AR protein expression (Fig. 4a (i-ii)). A modified TransAM
transcription factor ELISA (45496, Active Motif) was used
to evaluate activation of the AR. The TransAM assay is a
DNA-binding ELISA that facilitates the study of transcrip-
tion factor activation in nuclear cell extracts. The plate con-
sists of an immobilized oligonucleotide containing the HRE
binding site (5′-GGTACAnnnTGTTCT-3′) to which AR is
known to have high affinity [41]. AR binding to the oligo-
nucleotide was significantly increased in the presence of
rhPSAP (10 ng/ml) and R1881 (10 nmol/L) compared to
control (Fig. 4b (i-ii)). Nuclear translocation assays were
then utilised to monitor AR nuclear trafficking in the pres-
ence of rhPSAP plus or minus the anti-AR drug, enzaluta-
mide. Treatment of LetR cells with rhPSAP induced
significant translocation of the AR into the nucleus.
Enzalutamide alone successfully inhibited the nuclear
presence of AR in unstimulated cells. Combined treat-
ment of rhPSAP and enzalutamide significantly reduced
the nuclear-trafficking effect of rhPSAP (Fig. 4c (i) with
representative images in 4c (ii). When this experiment was
carried out in the endocrine-sensitive MCF7 cells there
was much less AR detected and no significant change in
AR nuclear localisation with treatments (Fig. 4c (iii), for
representative images see Additional file 7: Figure S3).
PSAP increases cell motility and invasiveness of
endocrine-resistant breast cancer cells with no significant
impact on the function of endocrine-sensitive cells
The impact of rhPSAP on cell migration in the endocrine-
resistant and sensitive cells was evaluated using a scratch
assay. rhPSAP at a range of 1−10 ng/ml induced a sig-
nificant increase in LetR cell migration after 24 hours
(Fig. 5a (i)), conversely, there was no impact on endocrine-
sensitive MCF7 cell migration following rhPSAP treatment
((Fig. 5a (ii)). Further functional studies investigated the im-
pact of rhPSAP on cell invasiveness. A Biocoat matrigel in-
vasion assay determined that LetR cells have innate invasive
properties that are not apparent in the endocrine-sensitive
MCF7 cells (Fig. 5b (i and iii). Upon treatment with rhPSAP
there was a significant increase in the numbers of inva-
sive LetR cells (Fig. 5b (ii)), whereas rhPSAP treatment
made no significant impact on the invasive potential of
the MCF7 cells (Fig. 5b (iv-v)). Knockdown of HOXC11
markedly impacted upon the invasive capacity of LetR
cells when cultured under vehicle and rhPSAP treatments
(Fig. 5c (i-v).
Inhibition of AR can diminish letrozole-resistant cell
proliferation and the pro-migratory impact of rhPSAP
The pro-migratory influence of PSAP could be successfully
attenuated by co-treating with the anti-AR drug (bicaluta-
mide) (Fig. 6a (i-ii)). Bicalutamide treatment alone did not
have any impact on cell migration (Fig. 6a (iii)). Follow-on
studies investigated the impact of anti-AR treatment on
LetR cell growth and it was observed that bicalutamide sig-
nificantly inhibited cell proliferation in both MTS and col-
ony forming assays (Fig. 6b (i-ii)).
Pre-operative serum levels of PSAP are significantly higher in
breast cancer patients whose disease subsequently recurred:
high levels of both PSAP and AR mRNA associate very
strongly with poor disease-free survival in endocrine-treated
breast cancers
Evaluation of secreted PSAP levels in a cohort of endocrine
resistant patient sera along with age-matched, non-recurrent
(See figure on previous page.)
Fig. 3 Prosaposin (PSAP), a known androgen receptor (AR) activator, is readily detectable in breast cancer cells that have high endogenous levels
of HOXC11 and AR protein. a Secreted PSAP protein levels were evaluated in conditioned media harvested from a range of breast cancer cell
lines that were designated endocrine-sensitive (MCF7, Aro) or endocrine-resistant (LY2, letrozole-resistant (LetR) and anastrozole-resistant (AnaR)).
PSAP ELISA detected significant levels of protein in the endocrine-resistant cells. b (i) Protein levels of AR were determined by western blot analysis of nuclear
protein cell lysate extracted from breast cancer cells (MCF7, LetR, MDA-MB-453, LY2 and SKBR3). (ii) Endocrine-resistant cells LY2 and LetR
exhibited >2 fold increase in AR nuclear protein expression compared to their endocrine-sensitive MCF7 counterparts. Image representative
of three experimental replicates. Error bars are representative of mean ± standard error of the mean (SEM) of three separate experiments. c (i) Transient
overexpression of HOXC11 in MCF7 cells resulted in a significant increase in the level of nuclear AR. Image representative of three experimental replicates.
Error bars are representative of mean ± SEM of three separate experiments. c (ii) Representative images of AR in MCF7 cells with transient overexpression
of pSPORT empty vector versus pSPORT HOXC11. d Elevated levels of PSAP, HOXC11 and AR in endocrine-resistant cells. §McIlroy et al., 2010. *p <0.05
**p <0.001. Tam tamoxifen, AI aromatase inhibitor
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controls (n = 34) were used to generate a training set; with
the aim to determine whether or not PSAP could distinguish
between patients sensitive or resistant to endocrine therapy.
The cutoff was set at 0.84 ng/μl, which was established from
the mean + 2 SD of PSAP serum levels in the non-recurrent
group (illustrated by dashed line Fig. 7a (i)). There was a sig-
nificant difference in PSAP expression levels between the re-
current and non-recurrent samples (p = 0.03) (Fig. 7a (ii)).
The median follow up of patients in this cohort was 35
months. These data indicate that approximately 35 % of
patients with postmenopausal breast cancer, who have
recurrence whilst on endocrine therapy, express PSAP
serum levels elevated above the threshold. Serum PSAP
levels elevated above the cutoff were significantly asso-
ciated with recurrence in an endocrine-treated cohort
of patients with breast cancer (p = 0.04) (Fig. 7a (i)).
Analysis of TCGA breast cancer dataset showed there to
be a weakly positive correlation between HOXC11 and
PSAP mRNA only in the luminal B subtype (rs 0.24). When
patients were further stratified to focus on those expressing
high levels of AR, the correlation between the two
genes was again only observed in subtypes of poorer
prognosis, in particular luminal B (rs 0.46) and basal
(rs 0.32) (Fig. 7b (i-ii)).
We then evaluated the impact of PSAP transcript levels
on endocrine-treated breast cancer patient outcome using
the Breastmark meta-analysis software [40]. The high ex-
pression group in each plot (blue) accounts for the upper
quartile of expression levels for a particular transcript and
the low expression group (red) the remaining 75 %. This
was applied to each of the individual datasets and the in-
formation was then combined to perform a global pooled
survival analysis; 661 samples were used in this compari-
son. The HR was generated using Cox regression and the
logrank test was used to assign significance to the HR.
High expression levels of PSAP transcript were found to
be strongly predictive of poor DFS (p = 0.03) with an HR
of 1.45 (Fig. 7c (i)). The association of PSAP with poor
outcome is also observed in an HR curve generated for
PSAP in TCGA dataset (Additional file 8: Figure S4a).
Moreover, when we combined high expression of both
PSAP and AR mRNA there was a more pronounced detri-
mental impact on patient DFS (p = 0.0003) with an HR of
2.2 (Fig. 7c (ii)) compared to either transcript alone
(Additional file 8: Figure S4b).
Discussion
HOX genes have been implicated in the development of
haematological and solid tumour malignancies [42], with
many studies focusing on their potential role in endo-
crine cancers [27, 28, 43]. HOX genes play vital roles in
body mapping during development and posterior HOX
genes in particular are under very tight regulation by estro-
gen [44]. It is therefore of interest to understand how the
abnormal rebooting of posterior HOXC genes in mammary
epithelial tumour cells can potentiate endocrine-resistant
cancer and the development of metastasis [21, 27, 45]. In
this current study we wanted to further elucidate the role
of HOXC11 with regard to endocrine resistance and ster-
oidal adaptability in breast cancer. RNA-seq experiments
identified 1,919 DEGs when HOXC11 was silenced in
endocrine-resistant breast cancer. Analysis of genes
harbouring an HRE in the proximal promoter resulted
in a novel motif with significant sequence similarity to
AR and GR. Filtering of the data using motif mapping
identified 29 putative direct HOXC11 target genes includ-
ing PSAP which is a known AR activator [46]. HOXC11
recruitment to the DNA was found to be highly responsive
to the steroid environment. We observed that HOXC11 re-
cruitment to the proximal PSAP promoter is impaired by
treatment with estrogen in endocrine-resistant cell lines.
This is likely due to the fact that a number of posterior
HOXC genes are estrogen-repressed [27], the exact
mechanism is unknown but it could be postulated to
be due to chromatin remodelling [47]. It is therefore notable
that there was no significant alteration in HOXC11
(See figure on previous page.)
Fig. 4 Androgen receptor (AR) protein is upregulated and transcriptionally activated in letrozole-resistant (LetR) cells treated with recombinant prosaposin
(PSAP); the effect of PSAP can be diminished by co-treatment with the anti-AR drug enzalutamide (Enza). a (i) Western blot analysis was used to quantify
AR protein levels in LetR cells treated with recombinant human PSAP (rhPSAP) (10 ng/ml) versus control (Tris–HCl). (ii) Densitometry values from separate
experiments. Error bars are representative of mean ± standard error of the mean (SEM) of three separate experiments. b (i) Modified TransAM assay was
used to evaluate AR recruitment to a direct AR binding sequence 5′ – TGTTCT – 3′ when LetR cells are cultured in the presence of rhPSAP.
Results are representative of two separate experiments (ii) In LetR cells the AR binds the direct AR consensus sequence in the presence of
either R1881 or rhPSAP c. Nuclear translocation assays were used to observe the trafficking of AR in aromatase-inhibitor (AI)-resistant LetR
cells, as visualised by the detection of immunofluorescently labelled AR within the nucleus. c (i) rhPSAP treatment significantly increased AR
nuclear translocation in LetR cells (p <0.0001). rhPSAP and Enza combination treatment significantly decreased AR nuclear translocation in
LetR cells (p <0.05). Error bars are representative of mean ± SEM of three separate experiments. Anti-AR drug treatment (Enza) significantly
decreased AR nuclear translocation in LetR cells (p <0.05). (ii) There was no change in AR nuclear translocation in MCF7 cells following treatment with
either rhPSAP or Enza individually or with a combination of both rhPSAP and Enza. Error bars are representative of mean ± SEM of three separate
experiments. (iii) Representative images of AR nuclear translocation in LetR cells following individual treatments with rhPSAP and Enza and combination
treatments: *p <0.05, **p <0.001, ***p <0.0001. HRE hormone response element, Veh vehicle, DAPI 4′, 6-diamidino-2-phenylindole
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recruitment in the AI-resistant cells treated with andro-
stenedione; suggesting alternate patterns of HOXC11 re-
cruitment can be dictated by the steroid microenvironment.
The upregulation of PSAP gene expression by HOXC11
in endocrine-resistant breast cancer cells was of inter-
est primarily due to its association with tamoxifen re-
sistance [29], but also because of its potential as an AR
activator. Previous studies by Koochekpour et al. dem-
onstrated PSAP to cause ligand-independent activation
of AR in prostate cancer via activation of the PI3K
pathway [46]. To this end we decided to explore whether
or not PSAP can also activate AR in AI-resistant breast
cancer cells in the presence of unconverted endogenous
androgens. AR transcription factor activity assays demon-
strated successful activation of AR by treatment with
rhPSAP, which was of similar magnitude to R1881 ex-
posure. This was further validated by nuclear transloca-
tion experiments demonstrating that AR activation by
PSAP in resistant cells could be attenuated by treatment
with an anti-AR drug. The majority of research articles
Fig. 6 Inhibition of androgen receptor (AR) can diminish letrozole-resistant (LetR) cell proliferation and the pro-migratory impact of recombinant
human prosaposin (rhPSAP). a Scratch assays were utilised to investigate the impact of rhPSAP on the migratory capacity of aromatase inhibitor
(AI)-resistant LetR cells. Anti-AR, bicalutamide (Bica), treatment did not significantly impact on the migratory capacity of AI-resistant LetR cells over
48 hours (i); rhPSAP treatment (10 ng/ml) significantly increased LetR cell migration over 48 hours (ii). Combination treatment with rhPSAP and
bicalutamide significantly inhibited rhPSAP-mediated cell migration in AI-resistant LetR cells over 48 hours (iii). b (i) MTS and (ii) colony forming assays
were performed to assess the impact of bicalutamide on AI cell proliferation. Treatment of AI-resistant cells with the anti-AR drug, bicalutamide, reduces
cell proliferation in LetR. Error bars are representative of mean ± standard error of the mean from three separate experiments. *p <0.05, **p <0.001. VEH
vehicle, COMBO combination
(See figure on previous page.)
Fig. 5 Prosaposin (PSAP) increases cell motility and invasiveness of letrozole-resistant (LetR) breast cancer cells with negligible impact on the function of
endocrine-sensitive cells. a (i) In vitro scratch assays were used to evaluate the impact of recombinant human PSAP (rhPSAP) on cell migration. Cell migration
was significantly enhanced in LetR cells exposed to increasing doses of rhPSAP with maximal impact observed with 10 ng/ml PSAP treatment (p <0.0001) (ii),
conversely, there were no changes in cell migration observed in MCF7 cells (not significant (n.s.). Error bars are representative of mean ± standard error of the
mean (SEM) of three separate experiments. b (i-ii) Using matrigel invasion chambers it was determined that the invasive potential of LetR cells was greatly
amplified when cells were cultured in the presence of rhPSAP (10 ng/ml) (40 hours) compared to their endocrine-sensitive counterparts, MCF7 which were
unresponsive to treatment (iii-iv). b (v) Bar-chart representing data from rhPSAP invasion assay in LetR and MCF7. Error bars are representative
of mean ± SEM of three separate experiments. c Transfection of LetR cells with siRNA-HOXC11 significantly inhibits cell migration (i-ii), furthermore, treatment
of cells with rhPSAP (10 ng/ml) (60 hours) does not stimulate cell invasion when HOXC11 is knocked down (iii-iv). c (v) Data from rhPSAP invasion assay in
LetR +/− rhPSAP. Error bars are representative of mean ± SEM from four separate experiments: *p <0.05, **p <0.001, ***p <0.0001. Scram veh
scrambled vehicle
Ali et al. Breast Cancer Research  (2015) 17:123 Page 14 of 19
Fig. 7 (See legend on next page.)
Ali et al. Breast Cancer Research  (2015) 17:123 Page 15 of 19
investigating the role of AR and/or androgens in breast
cancer have concluded that male sex hormones and recep-
tors have an inhibitory impact on breast cancer cell
growth [13, 48, 49]. However, if we consider the
uniquely androgenic steroid environment that arises
from treatment with an AI it should be queried
whether this assumption is still relevant in the event
of recurrence with this class of drug.
PSAP had previously been reported to stimulate ER-
positive endocrine-sensitive breast cancer cell growth
[50], however, in the resistant setting, no significant impact
on cell growth was observed (Additional file 9: Figure S5).
The focus of functional studies was shifted to evaluate the
impact of PSAP on cell migration. Treatment of cells with
rhPSAP demonstrated that only endocrine-resistant breast
cancer cells respond to the pro-migratory and pro-invasive
effects of the protein. Further experiments indicated that
HOXC11 upregulation is required for the pro-invasive im-
pact of PSAP to manifest fully, suggesting that HOXC11
expression is key to development of the aggressive pheno-
type. Increased responsiveness in resistant cells may be due
to a number of unexplored factors including expression of
cell surface receptors capable of binding PSAP [51] or acti-
vation of specific signalling pathways [30]. Indeed, PSAP
does appear to induce activation of p-AKT in breast cancer
cells in vitro (Additional file 10: Figure S6a and b). This
leads to the appealing possibility of identifying new hall-
marks of resistance to endocrine therapy and the elucida-
tion of novel drug targets. The clinical potential of PSAP is
highlighted by the significantly elevated levels of the protein
detected in serum from breast cancer patients who experi-
enced disease recurrence on endocrine therapy.
HOXC11 and PSAP mRNA levels are strongly correlated
in a primary breast cancer cohort (rs = 0.7692, n = 51). Fur-
ther analysis of TCGA datasets also demonstrate a cor-
relation between HOXC11 and PSAP transcript levels,
specifically in luminal B breast cancer in which AR is
elevated (rs = 0.46). HOXC11 over-expression in MCF7
cells results in a significant increase in nuclear AR
suggesting that HOXC11 upregulation may be a major
determinant of the adaptive process. In our AI-resistant
breast cancer model we have shown that PSAP is cap-
able of upregulating and activating AR in the context of
high HOXC11 expression. Collectively these data sug-
gest that the tumour promotional activation of AR may
be an adaptive response primarily in cancers exhibiting
dysregulated estrogen signalling. Importantly these findings
open up the possibility of utilizing anti-androgens in the
treatment of a specific subtype of breast cancer expressing
high levels of AR and PSAP, which may not exhibit sus-
tained response to endocrine therapy. Studies by other
groups [16] have shown AR to be co-opted as a tran-
scription factor in place of ER in the apocrine subtype;
in our model we have also observed AR recruitment to
some, but not all, ER targets evaluated (unpublished
observations). Further investigations into the AR tran-
scriptome in AI-resistant breast cancer will help eluci-
date which processes are being impacted. We would
purport from these observations in AI-treated breast
cancer (in which estrogen signalling has been dysregulated)
that tumour cells have the potential to adapt and utilize
bioavailable steroids such as those of adrenal origin: 75 % of
breast tumours are positive for AR and so it is of interest to
evaluate how these cells adapt to the preponderance of cir-
culating androgens that occurs during prolonged treatment
with AI therapy. Evidence that this may be a mechanism of
resistance is emerging from clinical data suggesting
that levels of androgens, and more specifically andro-
stenedione, are increased in breast cancers refractory to AI
therapy [52]. Such disruption of normal hormonal homeo-
stasis of the breast will result in perturbation of normal
mammary epithelial maintenance [53] and this is what we
hypothesize may be contributing to the development of
endocrine resistance.
Conclusion
This study is supportive of a growing consensus that high
levels of AR may have a crucial role to play in the
(See figure on previous page.)
Fig. 7 Pre-operative serum levels of prosaposin (PSAP) are significantly higher in breast cancer patients whose disease subsequently recurred. High levels
of both PSAP and androgen receptor (AR) mRNA are very strongly associated with poor disease-free survival (DFS) in endocrine-treated breast cancer. a A
commercially available ELISA kit for human PSAP was used to quantify serum levels of the secreted protein in sera from breast cancer patients. PSAP levels
were evaluated in a subset of endocrine-resistant patients versus age-matched controls. (i) The non-recurrent control group was used to
generate a training set to establish a cutoff value of 0.84 ng/μl (median + 2 SD) to distinguish between patients sensitive and resistant to
endocrine therapy (dashed horizontal line). The median follow up of the cohort was 35 months. Preliminary findings indicate approximately
35 % of postmenopausal breast cancer patients who had recurrent disease whilst on endocrine therapy expressed PSAP serum levels elevated above the
cutoff (p = 0.04). (ii) Levels of PSAP detected in sera from patients with recurrent breast cancer was significantly higher than those of endocrine-responsive
patients (p = 0.03). b (i) Breast cancer patients (The Cancer Genome Atlas dataset (TGCA) with high androgen receptor (AR) expression (upper quartile) were
selected and Spearman’s correlation between HOXC11 and PSAP was calculated for each subtype: gray luminal A, blue luminal B, red basal,
green HER2 (n = 199). (ii) Tabulated results show Spearman’s correlation between HOXC11 and PSAP mRNA in AR-high breast cancers per
subtype. c (i) Meta-analysis of transcript levels in breast cancer patients (n = 661) indicates that PSAP mRNA is a significant predictor of poor
response to endocrine treatment in endocrine-treated patients (p = 0.03; hazard ratio (HR) 1.4). (ii) Patients expressing high mRNA levels of both PSAP
and AR experience much shorter periods of DFS reflected in an HR of 2.2 (p = 0.0003). BrCa breast cancer, HER2 human epidermal growth factor 2
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development of endocrine resistance [19, 20]. Notably, we
have identified a secreted marker, PSAP, which may have
utility in directing anti-AR second-line therapy for patients
failing on conventional endocrine treatment. In conclusion,
steroid receptor interplay may exert a more dynamic and
influential role in endocrine resistance than previously
thought. To this end a further exploration of the role of the
AR, in the development of AI resistance in particular, is
warranted.
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Additional file 1: Figure S1. a Modified TransAM assay was used to
evaluate androgen receptor (AR) recruitment to a direct AR binding sequence
5′ – TGTTCT – 3′. LNCaP steroid-dependent prostate cancer cells were evaluated
as a positive control. Both LNCaP and letrozole-resistant (LetR) cells were
cultured in the presence of R1881 (10 nmol/L), recombinant human prosaposin
(rhPSAP) (10 ng/ml) and androstenedione (100 nmol/L). b Optimal AR antibody
concentration was evaluated using R1881 (10 nmol/L) LNCaP nuclear
lysate. An antibody dilution of 1:250 provided optimal signal-noise ratio. HRE
human response element. (PDF 94 kb)
Additional file 2: Table: HOXC11 KD downregulated genes. HOXC11
differentially expressed genes (DEGs) downregulated after HOXC11
knockdown, ranked by p value. (PDF 1500 kb)
Additional file 3: Table: HOXC11 KD upregulated genes. HOXC11
differentially expressed genes (DEGs) upregulated after HOXC11
knockdown, ranked by p value. (PDF 259 kb)
Additional file 4: Figure S2. a (i) Validation of HOXC11 target gene,
GREB1, in LY2 cells in which HOXC11 was knocked down by siRNA. (ii)
Levels of concomitant GREB1 decrease when HOXC11 is silenced is
comparable to alterations observed in HOXC11 RNA-seq data. b The top
novel motif returned from MEME was then compared to all known motifs
annotated in the JARSPAR database (JARSPAR CORE 2014) using the TOMTOM
program. The top matched motif is shown to be androgen receptor (AR)
(p value: 2.26e-6) and the second most similar motif is NR3C1
glucocorticoid receptor (GR) (p value: 2.81e-4). (PDF 209 kb)
Additional file 5: Table: Androgen receptor (AR) motif results
p <0.001. A 400-bp-sized window surrounding starting sites of HOXC11
target genes was selected for AR motif searching. The searching process
was performed using the FIMO program available in MEME-suite with the
p value significant cutoff set at 0.001. (PDF 804 kb)
Additional file 6: Table: Estrogen receptor (ER) motif results
(p <0.001). A 400-bp-sized window surrounding starting sites of HOXC11
target genes was selected for ER motif searching. The searching process
was performed using the FIMO program available in MEME-suite with the
p value significant cutoff set at 0.001. (PDF 198 kb)
Additional file 7: Figure S3. Representative images of androgen receptor
(AR) nuclear translocation in MCF7 cells following individual treatments with
recombinant human prosaposin (rhPSAP) and enzalutamide (Enza) and
combination treatments. (PDF 114 kb)
Additional file 8: Figure S4. a Hazard ratio (HR) curve was generated
for prosaposin (PSAP) using the TCGA dataset. PSAP expressions between
25 and 75 % quantiles have a HR consistently >1. b Androgen receptor
(AR) mRNA does not associate with poor disease-free survival (DFS) in
endocrine-treated breast cancer. Kaplan-Meier survival curves were generated
to assess the impact of high androgen receptor transcript levels on survival of
endocrine-treated patients with breast cancer (n = 661). (PDF 204 kb)
Additional file 9: Figure S5. An MTS assay was utilised to assay the
impact of increasing doses of recombinant human prosaposin (rhPSAP)
on letrozole-resistant (LetR) cell proliferation after 24 hours treatment. No
change in LetR cell proliferation was detected following increased doses
in rhPSAP (n = 3). (PDF 86 kb)
Additional file 10: Figure S6. a Letrozole-resistant (LetR) cells were
treated with increasing doses of recombinant human prosaposin (rhPSAP).
p-AKT expression in these cells showed a dose-dependent increase with
rhPSAP treatment (n = 3). b In LetR cells, there is increased protein expression
of p-AKT when treated with rhPSAP. However, when treated with BEZ235
(PI3K inhibitor), there is marked reduction in p-AKT expression. This reduction
is also similarly seen in the combination group of rhPSAP and BEZ235
treatments (n = 3). (PDF 138 kb)
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